CN116492372A - Formula of traditional Chinese medicine for feeding lucid ganoderma to form bezoar by cattle and application of formula - Google Patents
Formula of traditional Chinese medicine for feeding lucid ganoderma to form bezoar by cattle and application of formula Download PDFInfo
- Publication number
- CN116492372A CN116492372A CN202310724706.1A CN202310724706A CN116492372A CN 116492372 A CN116492372 A CN 116492372A CN 202310724706 A CN202310724706 A CN 202310724706A CN 116492372 A CN116492372 A CN 116492372A
- Authority
- CN
- China
- Prior art keywords
- bezoar
- cattle
- feeding
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283690 Bos taurus Species 0.000 title claims abstract description 99
- 206010004542 Bezoar Diseases 0.000 title claims abstract description 75
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 241000222336 Ganoderma Species 0.000 title claims abstract description 23
- 241000804384 Cynomorium songaricum Species 0.000 claims description 17
- 241000893536 Epimedium Species 0.000 claims description 16
- 241000237502 Ostreidae Species 0.000 claims description 16
- 235000018905 epimedium Nutrition 0.000 claims description 16
- 235000020636 oyster Nutrition 0.000 claims description 16
- 240000008397 Ganoderma lucidum Species 0.000 claims description 13
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 13
- 241000202726 Bupleurum Species 0.000 claims description 8
- 244000046146 Pueraria lobata Species 0.000 claims description 8
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 5
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 abstract description 52
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 abstract description 21
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 abstract description 20
- 239000004380 Cholic acid Substances 0.000 abstract description 20
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract description 20
- 229960002471 cholic acid Drugs 0.000 abstract description 20
- 235000019416 cholic acid Nutrition 0.000 abstract description 20
- 238000000034 method Methods 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 34
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 31
- 210000000941 bile Anatomy 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 17
- 235000012000 cholesterol Nutrition 0.000 description 12
- 208000001130 gallstones Diseases 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 244000309464 bull Species 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000000232 gallbladder Anatomy 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000006911 nucleation Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 239000004575 stone Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 201000001883 cholelithiasis Diseases 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 241000748223 Alisma Species 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000000927 lithogenic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229930192014 saikosaponin Natural products 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Marine Sciences & Fisheries (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine preparation, and in particular relates to a traditional Chinese medicine formula for feeding lucid ganoderma to form bezoar and application thereof, wherein the formula comprises the following components in parts by weight: the invention provides a traditional Chinese medicine formula for artificially cultivating bezoar, which is used for successfully cultivating bezoar, and the cultivated bezoar has no influence on the body functions of cattle in the cultivating process, and the content of bilirubin and cholic acid is measured, so that the result accords with 2000 edition pharmacopoeia regulations, and compared with the cultivated bezoar, the bilirubin and cholic acid content of the cultivated bezoar is higher than that of natural bezoar, the content of the bilirubin and cholic acid of the cultivated bezoar is more uniform.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine preparation, in particular to a traditional Chinese medicine formula for feeding lucid ganoderma to form bezoar and application thereof.
Background
Calculus bovis (cow bezoar) is gall-stone of gall bladder of bovine of the phylum chordopoda, mammal. The "gall bladder yellow" or "yolk" is produced in the gall bladder, the "tube yellow" is produced in the bile duct, and the "liver yellow" is produced in the liver duct. The bezoar is usually oval, light in weight, and has a golden to brownish surface, and is fine and glossy. The bezoar is considered to have faint scent, slightly bitter and sweet taste and flat nature. Can be used for relieving fever, removing toxic materials, and arresting convulsion. It is indicated for high fever, coma, mania, infantile convulsions and convulsions by oral administration, swelling and pain in throat, aphtha, carbuncle, swelling and uremia by external application.
Bezoar is a traditional Chinese medicine in China, and is gall-stone growing in gall bladder of cattle, and gall-stone formation must pass through three stages: 1. saturated bile formation; 2. nucleation; 3. and (5) stone growth. Gallstone formation is the result of the formation, nucleation and stasis of saturated bile, and the interaction of three lithogenic elements, the common physicochemical mechanism of which is the process by which certain lipids, inorganic salts or organic salts of bile are extracted from the bile beyond their maximum solubility in bile.
Cholesterol in bile must be in a dissolved state during transport from the liver to the duodenum. If crystals are formed by precipitation from bile, the crystals can form gallstones when grown under certain conditions.
Natural bezoar is very precious, the international price is even higher than gold, and at present, most of Chinese patent medicines containing bezoar components in the market in China are artificial bezoar, so that the efficacy is also greatly reduced.
Disclosure of Invention
The invention uses the medicinal components of traditional Chinese medicines such as lucid ganoderma, radix bupleuri, rhizoma alismatis and the like to cause supersaturation of cholesterol in oxgall, uses oyster medicinal materials rich in calcium components to increase calcium salt in gall so as to cause nucleation of gall-stone, uses the medicinal components of two traditional Chinese medicinal materials such as epimedium and cynomorium songaricum to increase cholesterol and reduce secretion of bile acid, and uses the medicinal components of kudzuvine root to relax smooth muscle of gall bladder so as to cause gall-stone stagnation and gall-bladder expansion, thereby forming gall-stone and causing stone growth. The specific scheme is as follows:
a traditional Chinese medicine formula for feeding lucid ganoderma to form bezoar for cattle comprises the following formula components in parts by weight: 50-70 g of lucid ganoderma, 20-40 g of radix bupleuri, 20-40 g of rhizoma alismatis, 40-60 g of oyster, 20-40 g of epimedium herb, 20-40 g of cynomorium songaricum and 20-40 g of radix puerariae.
Further, the formula of the traditional Chinese medicine for feeding the lucid ganoderma to form the bezoar comprises the following components in parts by weight: 60g of lucid ganoderma, 30g of radix bupleuri, 30g of rhizoma alismatis, 50g of oyster, 30g of epimedium herb, 30g of cynomorium songaricum and 30g of radix puerariae.
The traditional Chinese medicinal materials adopted in the invention are all prepared traditional Chinese medicinal decoction pieces.
The action principle of the formula is as follows:
ganoderma lucidum: the Ganoderma contains Ganoderma triterpene and Ganoderma polysaccharide, and can be used for reducing blood cholesterol, lipoprotein and triglyceride. The cholesterol and triglyceride content in blood is mainly regulated by liver, and when the amount of cholesterol and triglyceride is relatively large, the amount of the two components synthesized by liver is relatively small; otherwise, the liver will synthesize a bit more. The Ganoderma triterpene can regulate liver synthesis amount, and ganoderan can reduce intestinal tract absorption amount to reduce blood cholesterol, lipoprotein and triglyceride.
Bupleurum root: radix bupleuri enters liver meridian, has effects of dispersing stagnated liver qi for relieving qi stagnation, contains saikosaponin, and has effects of lowering blood plasma cholesterol, relieving liver injury, promoting bile secretion, etc.
Oriental Waterplantain rhizome: the rhizoma alismatis can reduce the cholesterol and fat content in blood, and can reduce triglyceride while reducing serum cholesterol.
Oyster: the calcium supplement agent has an absorption rate of 39%, increases the calcium content in the bile of the bovine blood, and is supersaturated so that the calcium bilirubin is combined with the bilirubin to form calcium bilirubin as a crystal nucleus of gall stone. Calcium salts are important components of gallstones, calcium can combine with several anions normally existing in bile such as bilirubin to form a precipitate, bilirubin calcium is a component of cholesterol stone nuclei, calcium salts are crystal nuclei for cholesterol nucleation and are seeds for crystal growth, and calcium ions in bile are increased to cause increased deposition in combination with bilirubin and cholesterol, so that the gallstones are formed.
Epimedium herb: contains flavonoid compounds and has estrogen effect, and modern researches prove that the product has a plurality of pharmacological effects such as estrogen effect and the like.
Cynomorium songaricum: modern researches have proved that cynomorium songaricum has various pharmacological actions like female hormone. The estrogen can stimulate lipoprotein receptor of liver, increase cholesterol in feed taken by liver, and secrete more cholesterol into bile, and can inhibit chenodeoxycholic acid synthesis, reduce chenodeoxycholic acid pool size, and increase the ratio of cholic acid and deoxycholic acid in cholic acid pool, which can increase cholesterol secretion by 40%.
Radix Puerariae: modern pharmacological research shows that puerarin, progesterone and other chemical substances are contained in pueraria. The progestogen can inhibit the excitation of smooth muscle of gall bladder, relax smooth muscle, inhibit the expansion of gall bladder, and treat cholestasis, thereby facilitating the growth of ox gall-stone.
On the other hand, the invention provides an application of a traditional Chinese medicine formula for feeding lucid ganoderma to form bezoar by cattle, which comprises the following steps:
(1) Healthy aged cattle are selected, and the aged cattle are better;
(2) 50-70 g of traditional Chinese medicine ganoderma lucidum, 20-40 g of radix bupleuri, 20-40 g of rhizoma alismatis, 40-60 g of oyster, 20-40 g of epimedium herb, 20-40 g of cynomorium songaricum and 20-40 g of radix puerariae are mixed together and crushed, and then added with feed or drenched to be taken by cattle;
(3) Continuously feeding for 25-35 days, normally feeding for 10-12 months, and taking out calculus bovis.
Further, the invention provides an application of a traditional Chinese medicine formula for feeding lucid ganoderma to form bezoar by cattle, which comprises the following steps:
(1) Healthy aged cattle are selected, and the aged cattle are better;
(2) 60g of traditional Chinese medicines of ganoderma lucidum, 30g of bupleurum, 30g of rhizoma alismatis, 50g of oyster, 30g of epimedium, 30g of cynomorium songaricum and 30g of kudzuvine root are mixed and crushed together, and then added with feed or drenched to be taken by cattle;
(3) Continuously feeding for 25-35 days, normally feeding for 10-12 months, and taking out calculus bovis.
Further, when the Chinese medicinal materials are fed to the cattle, 230-290 g of the Chinese medicinal materials are fed once a day.
Further, more than three cows are selected as mother cows with five years of farrowing in our country.
The beneficial effects of the invention are as follows:
1. the invention adopts the medicines to cultivate the bezoar, can reduce the injury of the bezoar caused by the original operation nuclear-placement cultivation of the bezoar, screens out that the optimal cultivated bezoar is more than three cows and five years old, obviously improves the yellow yield, can maximally reach 100.7 g, can effectively relieve the bezoar raw material shortage dilemma in China, and reduces the direct economic cost of the cultivated bezoar.
2. The invention greatly shortens the cultivation time of the bezoar to 10-12 months, has more input-output operation times and effectively enhances the business operation capability of enterprises.
3. In the experimental process of the invention, uncomfortable phenomenon of the cow is not found, and the integral function of the cow is not affected by the formation of the cow.
4. The invention provides a traditional Chinese medicine formula for artificially cultivating bezoar, which is used for successfully cultivating bezoar, the content of bilirubin and cholic acid of the bezoar cultivated by the invention is measured, the bilirubin is more than 65%, the cholic acid is more than 14%, the results all accord with the regulations of the 2000 edition pharmacopoeia, and the content of bilirubin and cholic acid is higher than that of natural bezoar and is more uniform.
Drawings
FIG. 1 is a thin layer chromatography identification chart of taurocholate in experiment one;
FIG. 2 is a thin layer chromatography identification chart of bezoar bilirubin in experiment II;
FIG. 3 is a photograph of bile taken in experiment 5;
FIG. 4 is a photograph of the initial formation of bezoar on the inner wall of the bottle in experiment 5.
Detailed Description
Example 1
An application of a traditional Chinese medicine formula for feeding lucid ganoderma to form bezoar by cattle comprises the following steps:
(1) Healthy aged cattle are selected, and the aged cattle are better;
(2) 50g of traditional Chinese medicines of ganoderma lucidum, 20g of radix bupleuri, 20g of rhizoma alismatis, 40 g of oyster, 20g of epimedium herb, 20g of cynomorium songaricum and 20g of radix puerariae are mixed and crushed together, and then added with feed to be taken by cattle;
(3) And after continuous feeding for 25 days, feeding for 10 months normally, and taking out the bezoar.
Moreover, when the Chinese medicinal materials are fed to the cattle, 230 g of the Chinese medicinal materials are fed once a day.
And more than three cows are selected as mother cows with five years of farrowing in our country.
Example 2
An application of a traditional Chinese medicine formula for feeding lucid ganoderma to form bezoar by cattle comprises the following steps:
(1) Healthy aged cattle are selected, and the aged cattle are better;
(2) 70 g of traditional Chinese medicine ganoderma lucidum, 40 g of bupleurum, 40 g of alisma orientale, 60g of oyster, 40 g of epimedium herb, 40 g of cynomorium songaricum and 40 g of kudzuvine root are mixed and crushed together, and then the mixture is added into a capsule for administration;
(3) After continuous feeding for 35 days, normal feeding is carried out for 12 months, and bezoar is taken out.
Moreover, when the Chinese medicinal materials are fed to the cattle, 290 g of the Chinese medicinal materials are fed once a day.
And more than three cows are selected as mother cows with five years of farrowing in our country.
Example 3
An application of a traditional Chinese medicine formula for feeding lucid ganoderma to form bezoar by cattle comprises the following steps:
(1) Healthy aged cattle are selected, and the aged cattle are better;
(2) 60g of traditional Chinese medicines of ganoderma lucidum, 30g of bupleurum, 30g of rhizoma alismatis, 50g of oyster, 30g of epimedium, 30g of cynomorium songaricum and 30g of kudzuvine root are mixed and crushed together, and then added with feed to be taken by cattle;
(3) After continuous feeding for 30 days, normal feeding is carried out for 11 months, and bezoar is taken out.
Moreover, when the Chinese medicinal materials are fed to the cattle, 260 g of the Chinese medicinal materials are fed once a day.
And more than three cows are selected as mother cows with five years of farrowing in our country.
Comparative example 1
The comparative example was the same as in example 3 except that the formulation was 30g of ganoderma lucidum, 10g of bupleurum, 15g of alisma orientale, 20g of oyster, 10g of epimedium, 10g of cynomorium songaricum and 10g of kudzuvine root.
Comparative example 2
The comparative example was the same as in example 3 except that the formulation was ganoderma lucidum 80g, bupleurum root 60g, alisma rhizome 60g, oyster 80g, epimedium 50g, cynomorium songaricum 50g, kudzuvine root 60 g.
Comparative example 3
The comparative example was the same as in example 3 except that the formulation was 30g of ganoderma lucidum, 10g of bupleurum, 15g of alisma orientale, 20g of oyster, 50g of epimedium, 50g of cynomorium songaricum and 60g of kudzuvine root.
Comparative example 4
This comparative example was the same as example 3, except that young bulls were selected as the cattle.
Comparative example 5
The comparative example was the same as example 3, except that the aged bulls were selected as the cattle.
Comparative example 6
This comparative example was the same as in example 3, except that the cattle were imported cows (siemens).
Comparative example 7
In this comparative example, a two-calf native birth female cattle was used, and the other operations were the same as in example 3.
Comparative example 8
This comparative example was the same as in example 3 except that a calfskin was selected as the calfskin.
Experimental part
Experiment 1
The bezoar, the natural bezoar and the cholic acid reference substance obtained in the embodiment 3 of the present invention are subjected to a thin-layer chromatography identification experiment of cholic acid, and specific results are shown in fig. 1, wherein A, D, G is the cholic acid reference substance, B, C is the bezoar obtained in the embodiment 3 of the present invention, E, F is the natural bezoar, and it can be seen from fig. 1 that the bezoar obtained in the embodiment 3 and the natural bezoar show fluorescent spots of the same color at the positions corresponding to the cholic acid of the reference substance.
Experiment 2
The bezoar obtained in the embodiment 3 of the present invention, the natural bezoar and the bilirubin reference substance are subjected to a bilirubin thin-layer chromatography identification experiment, and specifically as shown in fig. 2, wherein a is the bezoar obtained in the embodiment 3 of the present invention, B is the bilirubin reference substance, and C is the natural bezoar, and it can be seen from fig. 2 that the bezoar obtained in the embodiment 3 of the present invention and the natural bezoar both show fluorescent spots of the same color at positions corresponding to the bilirubin reference substance.
Experiment 3
The measurement of bilirubin and cholic acid content was carried out by taking one experiment and three natural bezoar as control experiments from each of bezoar obtained in examples 1 to 3, as shown in Table 1.
TABLE 1 bezoar bilirubin and cholic acid content
As can be seen from Table 1, the obtained bezoar bilirubin is above 65%, the cholic acid is above 14%, and the content of bilirubin and cholic acid of the cultivated bezoar and natural bezoar are determined, and the results of the content measurement are in accordance with the regulations of the pharmacopoeia of 2000 edition, and the content of bilirubin and cholic acid of the cultivated bezoar is higher than that of the natural bezoar, and the content of bilirubin and cholic acid of the cultivated bezoar is more uniform, because the feeding, the cultivation Huang Shichang and the like of the cultivated bezoar are guided by the optimal quality, and the natural bezoar is obtained by the even, and the time difference of bezoar in the bovine body is larger, so the quality is slightly different.
Experiment 4
Selecting 51 or more five-year old local farrowing cows, 3 young bull, 3 old bull, 3 or more Siemens cow, 3 two-year old local farrowing cows, 3-year old local farrowing cows in China, and the popularization and practice of the three-year old local farrowing cows in He Hao city in Mongolia, and checking by the He Hao city medicine check, wherein the experiment is divided into 11 groups:
group 1: feeding the native farrowing female cattle of China with ages of more than 14 and five years by adopting the method of the embodiment 1;
group 2: feeding the native farrowing female cattle of China with ages of more than 14 and five years by adopting the method of the embodiment 2;
group 3: feeding the native farrowing female cattle of China with ages of more than 14 and five years by adopting the method of the example 3;
group 4: 3 first three or more than five years old female cattle born in China in the nature are fed by adopting the mode of comparative example 1;
group 5: 3 first three or more than five years old female cattle born in China in the nature are fed by adopting the mode of comparative example 2;
group 6: 3 first three or more than five years old female cattle born in China in the nature are fed by adopting the mode of comparative example 3;
group 7: 3 young bull (comparative example 4) fed in the manner of example 3;
group 8: 3 old bulls (comparative example 5) were fed in the manner of example 3;
group 9: more than 3-head Siemens cows (comparative example 6) were fed by the method of example 3;
group 10: 3-head two-embryo domestic native farrowing female cattle (comparative example 7) are fed by the method of example 3;
group 11: 3 first one birth of native farrowing cow in China (comparative example 8) is fed by the method of example 3;
taking more than three non-yellow-medicated calves as control group, performing experiment, randomly selecting calves from each group for blood routine test during feeding for 2 months and 6 months, and measuring yellow yield, bilirubin content and cholic acid content of calculus bovis respectively, wherein the results are shown in tables 2-4, and are specifically as follows:
TABLE 2 blood routine for feeding cattle for 2 months with yellow-cultivated drug
As can be seen from table 2: in the blood of the cattle of the control group, the example and the comparative example, no obvious change occurs in the total number of red blood cells, white blood cells and white blood cell classification, no stone is formed in the cattle in the early stage of the yellow culture, after the yellow culture medicaments of the examples 1-3 are taken by the native birth female cattle of the five-year old China, the yellow culture medicaments of the comparative example 1-3 are taken by the native birth female cattle of the five-year old China, and the native birth female cattle of the two-year old China, the native birth female cattle of the China, the young bull, the aged bull and the Siemens cow of the three-year old are not changed in the conventional conditions, compared with the control group, so that the composition of the medicament formula and the process treatment adopted by the invention cannot influence the physical functions of the cattle.
TABLE 3 blood routine for feeding yellow-cultivated drug 6 months cattle
As can be seen from Table 3, in the blood routine of the cattle in the examples and the comparative examples, the white blood cell number and the neutrophil proportion are both increased and the lymphocyte proportion is decreased when the cattle is fed with the yellow-cultivation medicine for 6 months, showing that the stimulation of the organism to the yellow-cultivation medicine shows inflammatory reaction, and the immunity and the resistance of the organism are enhanced by the inflammatory reaction; the increase in white blood cell count of the comparative example was reduced relative to the example; this is because, during the yellow cultivation, the formulation of comparative examples 1-3 was changed compared with the present invention, and the yellow cultivation of comparative examples 4-8 was different from the present invention, so that the yellow cultivation amount was reduced, and the inflammatory reaction of the cattle was light compared with the examples.
In summary, the physiological and biochemical indexes of the cattle body after the administration of the medicine Huang Peihuang are affected to a certain extent, but the inflammatory reaction in the gall bladder and the bile excretion disorder are two basic factors in the bezoar formation mechanism, and the organism reaction caused by the factors does not affect the whole function of the cattle body, but also becomes a favorable condition and factor for early yellowing.
TABLE 4 yellow production of cattle cultivated
As can be seen from Table 4, the cattle of the examples and the comparative examples only have different amounts of bezoar, wherein the yellow production in the examples can reach 100.7 g, while the yellow production in the comparative examples 1-8 are 63.5, 58.2, 55.6, 24.8, 23.8, 45.6, 36.5 and 31.7 g respectively, and the yellow production is obviously reduced; the cholic acid content is also reduced by 2% -4%; the bilirubin content is reduced by 10% -22%; because the comparative examples 1-3 are adjusted in proportion to the formula of the yellow-cultivation medicines compared with the examples of the invention, and the comparative examples 4-8 are used for changing the selection of the yellow-cultivation cattle into young bull, old bull, import bull, two-born native farrowing cow and one-born native farrowing cow, the effect is also obviously reduced, which indicates that the formula of the yellow-cultivation medicines and the selection of the cattle are all key of the invention, and the technical scheme of the invention is optimal under the same ecological environment and technical conditions when the artificial bezoar cultivation is carried out.
Experiment 5
In experiment 4, 3 rd group of experiments were carried out, after taking the medicine for 3 months, one end was randomly extracted, and the bile was taken out, as shown in fig. 3, the color of the bile had begun to deepen, which means that bilirubin in the bile had begun to increase, at the same time, floccules and precipitates were formed in the bile, the bile was poured into a bottle and poured out, so that the residual bile in the bottle was naturally dried in the shade, as shown in fig. 4, it was seen that small crystals had formed on the inner wall of the bottle, and bezoar had been primarily formed.
Claims (6)
1. A traditional Chinese medicine formula for feeding lucid ganoderma to form bezoar is characterized by comprising the following formula components in parts by weight: 50-70 g of lucid ganoderma, 20-40 g of radix bupleuri, 20-40 g of rhizoma alismatis, 40-60 g of oyster, 20-40 g of epimedium herb, 20-40 g of cynomorium songaricum and 20-40 g of radix puerariae.
2. The traditional Chinese medicine formula for feeding cattle to form bezoar according to claim 1, which is characterized by comprising the following formula components in parts by weight: 60g of lucid ganoderma, 30g of radix bupleuri, 30g of rhizoma alismatis, 50g of oyster, 30g of epimedium herb, 30g of cynomorium songaricum and 30g of radix puerariae.
3. Use of a traditional Chinese medicine formulation for forming bezoar by feeding ganoderma lucidum according to claim 1 or 2, comprising the steps of:
(1) Healthy aged cattle are selected, and the aged cattle are better;
(2) 50-70 g of traditional Chinese medicine ganoderma lucidum, 20-40 g of radix bupleuri, 20-40 g of rhizoma alismatis, 40-60 g of oyster, 20-40 g of epimedium herb, 20-40 g of cynomorium songaricum and 20-40 g of radix puerariae are mixed together and crushed, and then added with feed or drenched to be taken by cattle;
(3) Continuously feeding for 25-35 days, normally feeding for 10-12 months, and taking out calculus bovis.
4. An application of a traditional Chinese medicine formula for forming bezoar by feeding lucid ganoderma by using a cattle according to claim 3, which is characterized by comprising the following steps:
(1) Healthy aged cattle are selected, and the aged cattle are better;
(2) 60g of traditional Chinese medicines of ganoderma lucidum, 30g of bupleurum, 30g of rhizoma alismatis, 50g of oyster, 30g of epimedium, 30g of cynomorium songaricum and 30g of kudzuvine root are mixed and crushed together, and then added with feed or drenched to be taken by cattle;
(3) Continuously feeding for 25-35 days, normally feeding for 10-12 months, and taking out calculus bovis.
5. The use of a formula of a cow's feeding ganoderma lucidum traditional Chinese medicine for forming cow's bezoar according to claim 3, wherein the traditional Chinese medicine is fed to the cow once a day, each time 230-290 g.
6. The use of a formula of a cow for feeding lucid ganoderma to form cow bezoar according to claim 3, wherein more than three cows are selected from the group consisting of five-year old female cows born in the nature of China.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310724706.1A CN116492372B (en) | 2023-06-19 | 2023-06-19 | Formula of traditional Chinese medicine for feeding lucid ganoderma to form bezoar by cattle and application of formula |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310724706.1A CN116492372B (en) | 2023-06-19 | 2023-06-19 | Formula of traditional Chinese medicine for feeding lucid ganoderma to form bezoar by cattle and application of formula |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116492372A true CN116492372A (en) | 2023-07-28 |
| CN116492372B CN116492372B (en) | 2023-09-12 |
Family
ID=87321561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310724706.1A Active CN116492372B (en) | 2023-06-19 | 2023-06-19 | Formula of traditional Chinese medicine for feeding lucid ganoderma to form bezoar by cattle and application of formula |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116492372B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1079652A (en) * | 1992-06-06 | 1993-12-22 | 河北农业大学 | Production process for culturing bezoar |
| CN101461826A (en) * | 2009-01-12 | 2009-06-24 | 周广礼 | Method for industrial production of bezoar by chemical method |
| CN102078332A (en) * | 2009-12-01 | 2011-06-01 | 汤明昌 | In-vitro cultured calculus bovis containing preparation for treating common cold in children and preparation method thereof |
| CN102302517A (en) * | 2011-08-25 | 2012-01-04 | 济南阿科普生物技术开发有限公司 | Method for producing calculus bovis with natural quality |
| CN102526108A (en) * | 2011-12-29 | 2012-07-04 | 余春生 | Method for commercial production of bezoar |
| CN104897787A (en) * | 2014-09-05 | 2015-09-09 | 吉林师范大学 | Method for simultaneous determination of six active components in Niuhuang Ninggong tablet |
| CN112156113A (en) * | 2020-10-21 | 2021-01-01 | 大余博一牛黄技术开发有限公司 | Method for cultivating bezoar in ox gall by Chinese herbal medicine induction |
-
2023
- 2023-06-19 CN CN202310724706.1A patent/CN116492372B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1079652A (en) * | 1992-06-06 | 1993-12-22 | 河北农业大学 | Production process for culturing bezoar |
| CN101461826A (en) * | 2009-01-12 | 2009-06-24 | 周广礼 | Method for industrial production of bezoar by chemical method |
| CN102078332A (en) * | 2009-12-01 | 2011-06-01 | 汤明昌 | In-vitro cultured calculus bovis containing preparation for treating common cold in children and preparation method thereof |
| CN102302517A (en) * | 2011-08-25 | 2012-01-04 | 济南阿科普生物技术开发有限公司 | Method for producing calculus bovis with natural quality |
| CN102526108A (en) * | 2011-12-29 | 2012-07-04 | 余春生 | Method for commercial production of bezoar |
| CN104897787A (en) * | 2014-09-05 | 2015-09-09 | 吉林师范大学 | Method for simultaneous determination of six active components in Niuhuang Ninggong tablet |
| CN112156113A (en) * | 2020-10-21 | 2021-01-01 | 大余博一牛黄技术开发有限公司 | Method for cultivating bezoar in ox gall by Chinese herbal medicine induction |
Non-Patent Citations (2)
| Title |
|---|
| MASAYA IWAMURO等: "A Bezoar Composed of Bilirubin Calcium, Calcium Carbonate, and Fatty Acid Calcium", 《CASE REP GASTROINTEST MED .》, pages 5742672 * |
| 陆基宗;: "牛黄及其三种代用品", 家庭中医药, no. 03, pages 64 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116492372B (en) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105795468A (en) | Composition having efficacy of losing weight | |
| JP2004002304A (en) | Method for using phytoestrogen and analogue thereof for manufacturing health adjuvant | |
| CN109045059A (en) | A kind of anti-aging, the composition for improving male's energy, preparation and the preparation method and application thereof | |
| CN105535505A (en) | Method for preparing medicine composition for treating hepatic calculus | |
| CN104706704A (en) | Maca compositions, and compound preparation and application thereof | |
| CN105850795A (en) | Intensive breeding method of Chinese soft-shell turtles | |
| CN113398078B (en) | Granular traditional Chinese medicine for improving ovarian reserve function and preparation method thereof | |
| CN104431643A (en) | Chinese herbal medicine Chinese soft shell turtle feed additive promoting growth and preparation method therefore | |
| CN104758556B (en) | A kind of compound preparation and preparation method thereof of anti-Heat stress | |
| CN116492372B (en) | Formula of traditional Chinese medicine for feeding lucid ganoderma to form bezoar by cattle and application of formula | |
| CN108991292A (en) | Enhanced water resistance aquatic biological resisting stress food calling additive and preparation method | |
| CN110507669B (en) | Refined bear gall powder and its use for treating cholecystitis gall-stone and improving gall-bladder function | |
| CN106668185A (en) | Pharmaceutical composition for preventing and treating cattle and sheep urinary stones | |
| CN108452240A (en) | A kind of antitumor Chinese medicine composition and its application | |
| CN112544812A (en) | Mixed-strain fermentation type Chinese herbal medicine additive for laying hens in later period of laying, and preparation method and application thereof | |
| CN110339315A (en) | A kind of mongolian veterinary drug feed addictive and preparation method thereof for promoting ewe ovulation to produce twin lamb(s) | |
| CN109464579A (en) | A kind of traditional Chinese medicine oral liquid and preparation method thereof for preventing and treating chicken coccidiasis | |
| CN104491222A (en) | Traditional Chinese medicine for treating bovine follicle cyst and preparation method thereof | |
| CN103720993A (en) | Traditional Chinese medicine composition for improving dam ovulation quality | |
| CN112691167B (en) | Traditional Chinese medicine composition for treating depression and preparation and application thereof | |
| CN106620117A (en) | Chinese patent medicine for treating enterogastritis, and preparation method of Chinese patent medicine | |
| CN106109916A (en) | A kind of Fructus Rosae Laevigatae health care oral liquid of slow down aging and preparation method thereof | |
| Pearl et al. | Effect of Moringa oleifera Consumption during Lactation and Early Post-weaning Period on Lipid Profile and Diet-induced Programming of Obesity in the Offspring of Wistar Rats | |
| CN116392509A (en) | Method for inducing cow to form bezoar | |
| CN112641806A (en) | Artificial bezoar and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |